PL3923971T3 - Analizowanie wpływu polirybonukleotydu na ciliogenezę - Google Patents
Analizowanie wpływu polirybonukleotydu na ciliogenezęInfo
- Publication number
- PL3923971T3 PL3923971T3 PL20704031.2T PL20704031T PL3923971T3 PL 3923971 T3 PL3923971 T3 PL 3923971T3 PL 20704031 T PL20704031 T PL 20704031T PL 3923971 T3 PL3923971 T3 PL 3923971T3
- Authority
- PL
- Poland
- Prior art keywords
- ciliogenesis
- polyribonucleotide
- analyzing
- effect
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157210 | 2019-02-14 | ||
PCT/EP2020/053774 WO2020165352A1 (en) | 2019-02-14 | 2020-02-13 | Treatment of ciliopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3923971T3 true PL3923971T3 (pl) | 2024-03-25 |
Family
ID=65440876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20704031.2T PL3923971T3 (pl) | 2019-02-14 | 2020-02-13 | Analizowanie wpływu polirybonukleotydu na ciliogenezę |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220211807A1 (pl) |
EP (2) | EP3923971B1 (pl) |
JP (2) | JP2022522412A (pl) |
KR (1) | KR20210127718A (pl) |
CN (1) | CN113423418A (pl) |
AU (1) | AU2020220636A1 (pl) |
BR (1) | BR112021014528A2 (pl) |
CA (2) | CA3225057A1 (pl) |
ES (1) | ES2974368T3 (pl) |
HU (1) | HUE065017T2 (pl) |
MX (1) | MX2021009388A (pl) |
PL (1) | PL3923971T3 (pl) |
WO (1) | WO2020165352A1 (pl) |
ZA (1) | ZA202106769B (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562192B (zh) | 2016-05-27 | 2023-08-15 | 创思瑞普泰克斯公司 | 用合成信使rna治疗原发性纤毛运动障碍 |
US20240123087A1 (en) * | 2021-03-19 | 2024-04-18 | Recode Therapeutics, Inc. | Polynucleotide compositions, related formulations, and methods of use thereof |
WO2022204053A1 (en) * | 2021-03-22 | 2022-09-29 | Recode Therapeutics, Inc. | Polynucleotide compositions, related formulations, and methods of use thereof |
WO2023014887A1 (en) * | 2021-08-04 | 2023-02-09 | The Trustees Of Indiana University | Methods of treating compromised lung function and assessing clinical improvement |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
ATE208369T1 (de) | 1997-08-13 | 2001-11-15 | Biontex Lab Gmbh | Neue lipopolyamine, deren darstellung und anwendung |
WO2001000708A1 (de) | 1999-06-25 | 2001-01-04 | Christian Plank | Kombinationen zur einführung von nucleinsäuren in zellen |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
FR2925491B1 (fr) | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules |
JP6561378B2 (ja) * | 2012-06-08 | 2019-08-21 | トランスレイト バイオ, インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
KR20150020288A (ko) * | 2012-06-08 | 2015-02-25 | 에트리스 게엠베하 | 메신저 rna의 폐전달 |
WO2014020723A1 (ja) | 2012-08-01 | 2014-02-06 | 株式会社コナミデジタルエンタテインメント | 処理装置、処理装置の制御方法、及び、処理装置のプログラム |
EA036400B1 (ru) * | 2013-06-28 | 2020-11-06 | Этрис Гмбх | Композиции для введения рнк в клетки |
CN107405412A (zh) * | 2014-11-10 | 2017-11-28 | 埃泽瑞斯公司 | 通过递送bmp编码rna诱导骨生成 |
CN109562192B (zh) * | 2016-05-27 | 2023-08-15 | 创思瑞普泰克斯公司 | 用合成信使rna治疗原发性纤毛运动障碍 |
GB201707212D0 (en) * | 2017-05-05 | 2017-06-21 | Ucl Business Plc | Gene therapy for ciliopathies |
-
2020
- 2020-02-13 WO PCT/EP2020/053774 patent/WO2020165352A1/en unknown
- 2020-02-13 CA CA3225057A patent/CA3225057A1/en active Pending
- 2020-02-13 PL PL20704031.2T patent/PL3923971T3/pl unknown
- 2020-02-13 AU AU2020220636A patent/AU2020220636A1/en active Pending
- 2020-02-13 MX MX2021009388A patent/MX2021009388A/es unknown
- 2020-02-13 KR KR1020217028846A patent/KR20210127718A/ko active Search and Examination
- 2020-02-13 HU HUE20704031A patent/HUE065017T2/hu unknown
- 2020-02-13 JP JP2021547511A patent/JP2022522412A/ja active Pending
- 2020-02-13 CA CA3129912A patent/CA3129912A1/en active Pending
- 2020-02-13 CN CN202080014297.0A patent/CN113423418A/zh active Pending
- 2020-02-13 US US17/431,146 patent/US20220211807A1/en active Pending
- 2020-02-13 EP EP20704031.2A patent/EP3923971B1/en active Active
- 2020-02-13 BR BR112021014528-1A patent/BR112021014528A2/pt unknown
- 2020-02-13 EP EP23164871.8A patent/EP4223306A3/en active Pending
- 2020-02-13 ES ES20704031T patent/ES2974368T3/es active Active
-
2021
- 2021-09-13 ZA ZA2021/06769A patent/ZA202106769B/en unknown
-
2024
- 2024-04-03 JP JP2024060297A patent/JP2024096766A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021009388A (es) | 2021-09-10 |
CA3225057A1 (en) | 2020-08-20 |
CA3129912A1 (en) | 2020-08-20 |
EP3923971C0 (en) | 2023-12-20 |
BR112021014528A2 (pt) | 2021-10-13 |
EP4223306A3 (en) | 2023-11-29 |
EP4223306A2 (en) | 2023-08-09 |
ES2974368T3 (es) | 2024-06-27 |
EP3923971A1 (en) | 2021-12-22 |
JP2022522412A (ja) | 2022-04-19 |
JP2024096766A (ja) | 2024-07-17 |
WO2020165352A1 (en) | 2020-08-20 |
ZA202106769B (en) | 2024-01-31 |
AU2020220636A1 (en) | 2021-07-29 |
US20220211807A1 (en) | 2022-07-07 |
HUE065017T2 (hu) | 2024-04-28 |
EP3923971B1 (en) | 2023-12-20 |
KR20210127718A (ko) | 2021-10-22 |
CN113423418A (zh) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA191264S (en) | Analyzing instrument | |
SG11202106762UA (en) | Analysing a body | |
GB201903347D0 (en) | Execution unit | |
EP3923971C0 (en) | ANALYSIS OF THE EFFECT OF A POLYRIBONUCLEOTIDE ON CILIOGENesis | |
CA189989S (en) | Cuvette | |
GB201903346D0 (en) | Execution unit | |
GB201903827D0 (en) | New compounds and methods | |
GB2582143B (en) | Execution unit | |
GB201903832D0 (en) | New compounds and methods | |
GB201903348D0 (en) | Execution unit | |
GB201902077D0 (en) | Biomarkers | |
GB2570742B (en) | Optical-interference analysis | |
GB201908045D0 (en) | Object analysis | |
CA189106S (en) | Fastener | |
SG11202113179WA (en) | Context detection | |
GB201900677D0 (en) | Biomarkers | |
GB201913110D0 (en) | New compounds and methods | |
GB201913035D0 (en) | Test | |
GB2580670B (en) | Monitoring | |
GB2583714B (en) | Non-Invasive Measurement | |
GB201903430D0 (en) | Assembly and device therefor | |
GB2585410B (en) | Analysis | |
GB2596002B (en) | Object analysis | |
GB2587622B (en) | Small fastener | |
GB201915837D0 (en) | Probe |